

# Cyclic designer scaffolds for the covalent targeting of proteins

How to target specific proteins at specific locations by exploiting the "power" of the covalent bond?

## Biology—the problem:


Functionally relevant sites are located on proteins at shallow (difficult-to-target) surfaces.

## Chemistry—the solution:

$\alpha,\beta$ -unsaturated ketones react with nucleophilic residues (e.g., cysteines)

Classical composite drugs contain two functional moieties:

Directing group (DG) +  
Chemical warhead (WH)



JNK-IN-8: an example of an acrylamide-based inhibitor; \* reactive carbon

## Goal:

To make efficient and safe covalent drugs

## State of the art:

Acrylamide-based (open-chain) fragments in composite drugs

Limitations:

- High off-target reactivity
- Limited control on potency (irreversible covalent bond)
- It is a "blunt" tool; specificity must come from the directing group

## Our solution:

A new cyclic warhead scaffold inspired by biologically active (terpenoid-like) chiral natural products



Advantages:

- Resilient to off-target thiols (e.g., GSH)
- Alternative nucleophile choice (e.g., histidine)
- It is a "sophisticated" tool: molecular shape, steric and electronic properties can all be controlled
- Synthetic addition of noncovalent DG at early or late stage


Protenic Kft, Budapest,  
Hungary  
remenyi.attila@protenic.hu  
Tel. +36 305680040

## Concrete examples:

- Targeting the protein-protein interactions (PPI) of mitogen-activated protein kinases (MAPK D-groove)<sup>1</sup>





ERK2\_Cys161




ERK2-adduct

- Targeting specific cysteines next to the ATP-pocket of c-Jun N-terminal kinase (JNK)<sup>2</sup> and other targets



JNK1\_Cys116




JNK1-adduct

1 Targeting a key protein-protein interaction surface on mitogen-activated protein kinases by a precision-guided warhead scaffold; Póti et al. Nat. Comm. 15. 8607 (2024)

2 Reversible covalent c-Jun N-terminal kinase inhibitors targeting a specific cysteine by precision-guided Michael-acceptor warheads; Bálint et al. Nat. Comm. 15. 8606 (2024)


3 PCT/HU2023/050079: Cyclic designer scaffolds for the covalent targeting of proteins via Michael addition (Europe and US; pending approval)

**A sterically crowded, electronically tunable cyclohexenone/pentenone warhead scaffold interferes with Mitogen-Activated Protein Kinase (MAPK)-mediated PPIs<sup>1</sup>**



- The electron withdrawing capacity of groups at C2 and C4 modulates binding affinity and make the cysteine adduct reversible due to steric crowding effects.
- Compounds occupy the hydrophobic part of the key MAPK D-groove and thus block protein partner binding to MAPKs.
- Compounds have a stereogenic center through which MAPK-specificity can be modulated.
- Hit compounds were extended by further functionalization of the C4 moiety and these contacted additional PPI surface features.
- New MAPK inhibitors interfere with MAPK-based signaling by directly binding to the MAPK D-groove cysteine and are efficient in perturbing MAPK signaling networks in cells.
- Ester moieties are replaced with alternative substituent groups making the compounds stable (PK studies in rat primary hepatocytes and blood).
- Proteome-wide specificity of the basic designs are explored (~5000 proteins, with native hold-up assay + mass spectrometry).

**Demonstration of modularity of the cyclic warhead designs: development of a JNK<sup>2</sup> ATP-pocket binding, cysteine targeting reversible covalent inhibitor**



- New reversible covalent inhibitors outperform state-of-the-art irreversible JNK-IN-8 regarding system-level specificity (tested on the human kinome panel; since the cyclic nature of the warhead limits accessibility to the critical carbon).
- New composite JNK inhibitors represent a range of JNK potency in a given cellular setting (which may be beneficial for tuning JNK inhibition; e.g., partial vs complete).
- Residence time can be modulated by tuning the electronic and steric properties around the Michael acceptor carbon atom.
- The reversible covalent inhibitors are resilient to GSH (since the reaction with off-target thiols is very dynamic and has a fast  $k_{chem\_off}$ ).
- Successful replacement of irreversible acrylamide-based warheads with new cyclic warheads showing comparable in vitro potency (starting out from known JNK DGs) but less capacity to bind to ABC transporters (relevance to multidrug resistance).

**Biomedical relevance:**

- for MAPK PPI interfering drugs: cancer and inflammatory diseases
- for composite inhibitors: new patentable alternatives
- in general: less off-targets and synthetic advantage